(CAH) Cardinal Health - Overview
Sector: Healthcare | Industry: Medical Distribution | Exchange: NYSE (USA) | Market Cap: 50.715m USD | Total Return: 59.6% in 12m
Pharmaceuticals, Medical Devices, Surgical Supplies, Laboratory Products
Total Rating 68
Safety 64
Buy Signal 0.33
Medical Distribution
Industry Rotation: -10.1
Industry Rotation: -10.1
Market Cap:
50.7B
Avg Turnover: 309M USD
Avg Turnover: 309M USD
ATR:
2.13%
Peers RS (IBD): 82.8
Peers RS (IBD): 82.8
Risk 5d forecast
Volatility24.2%
Rel. Tail Risk-8.98%
Reward TTM
Sharpe Ratio1.60
Alpha52.05
Character TTM
Beta0.221
Beta Downside0.073
Drawdowns 3y
Max DD18.14%
CAGR/Max DD2.30
EPS (Earnings per Share)
EPS CAGR: 17.21%
EPS Trend: 75.5%
EPS Trend: 75.5%
Last SUE: 2.03
Qual. Beats: 2
Qual. Beats: 2
Revenue
Rev. CAGR: 10.61%
Rev. Trend: 88.8%
Rev. Trend: 88.8%
Last SUE: 0.11
Qual. Beats: 0
Qual. Beats: 0
Warnings
Altman Z'' 0.00 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Description: CAH Cardinal Health
Cardinal Health (NYSE: CAH) is a diversified healthcare services and products firm that operates two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company supplies hospitals, health systems, pharmacies, ambulatory surgery centers, labs, and home-care patients with a broad portfolio that includes branded and generic drugs, specialty pharmaceuticals, over-the-counter items, and a wide range of medical-surgical devices such as gloves, needles, drapes, and procedure kits.
In fiscal 2023, Cardinal Health generated roughly $177 billion in revenue, with specialty pharmaceutical distribution growing about 7% year-over-year and operating earnings of $2.5 billion, reflecting a modest 1.4% operating margin. The firm’s cash flow from operations stood at $4.3 billion, supporting ongoing investments in supply-chain technology and expansion of its radiopharmaceutical business.
Key sector drivers include the accelerating shift toward high-margin specialty drugs, heightened focus on supply-chain resilience after recent drug-shortage events, and consolidation among healthcare providers that favors integrated distribution partners. For a deeper dive, you might explore ValueRay’s analyst tools.
- Generic pharmaceutical pricing pressures impact Pharmaceutical segment revenue
- Medical product supply chain disruptions increase distribution costs
- Healthcare provider consolidation affects customer base and pricing power
- Regulatory changes in drug distribution and medical device manufacturing
- Inflationary pressures on labor and transportation expenses reduce margins
Piotroski VR‑10 (Strict)
6.0
| Net Income: 1.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 10.52 > 1.0 |
| NWC/Revenue: -1.67% < 20% (prev 0.24%; Δ -1.91% < -1%) |
| CFO/TA 0.11 > 3% & CFO 6.10b > Net Income 1.67b |
| Net Debt (6.25b) to EBITDA (3.23b): 1.93 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (237.0m) vs 12m ago -2.47% < -2% |
| Gross Margin: 3.62% > 18% (prev 0.03%; Δ 358.8% > 0.5%) |
| Asset Turnover: 465.3% > 50% (prev 472.6%; Δ -7.26% > 0%) |
| Interest Coverage Ratio: 7.65 > 6 (EBITDA TTM 3.23b / Interest Expense TTM 316.0m) |
Altman Z''
0.00
| A: -0.07 (Total Current Assets 39.23b - Total Current Liabilities 43.31b) / Total Assets 58.08b |
| B: 0.03 (Retained Earnings 1.46b / Total Assets 58.08b) |
| C: 0.05 (EBIT TTM 2.42b / Avg Total Assets 52.54b) |
| D: 0.07 (Book Value of Equity 4.15b / Total Liabilities 60.78b) |
| Altman-Z'' Score: 0.00 = B |
Beneish M
-2.79
| DSRI: 1.00 (Receivables 13.66b/12.37b, Revenue 244.49b/222.12b) |
| GMI: 0.95 (GM 3.62% / 3.44%) |
| AQI: 1.49 (AQ_t 0.28 / AQ_t-1 0.18) |
| SGI: 1.10 (Revenue 244.49b / 222.12b) |
| TATA: -0.08 (NI 1.67b - CFO 6.10b) / TA 58.08b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of CAH shares?
As of April 16, 2026, the stock is trading at USD 211.83 with a total of 1,083,127 shares traded.
Over the past week, the price has changed by -1.53%, over one month by -2.41%, over three months by -0.52% and over the past year by +59.57%.
Over the past week, the price has changed by -1.53%, over one month by -2.41%, over three months by -0.52% and over the past year by +59.57%.
Is CAH a buy, sell or hold?
Cardinal Health has received a consensus analysts rating of 4.12.
Therefore, it is recommended to buy CAH.
- StrongBuy: 9
- Buy: 2
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CAH price?
| Analysts Target Price | 248.3 | 17.2% |
Cardinal Health (CAH) - Fundamental Data Overview
as of 12 April 2026
P/E Trailing = 31.0101 P/E Forward = 16.9205
P/S = 0.2073
P/B = 16.0657
P/EG = 1.6278
Revenue TTM = 244.49b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.23b USD
Long Term Debt = 8.35b USD (from longTermDebt, last quarter)
Short Term Debt = 680.0m USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.25b USD (from netDebt column, last quarter)
Enterprise Value = 56.97b USD (50.72b + Debt 9.03b - CCE 2.78b)
Interest Coverage Ratio = 7.65 (Ebit TTM 2.42b / Interest Expense TTM 316.0m)
EV/FCF = 10.35x (Enterprise Value 56.97b / FCF TTM 5.51b)
FCF Yield = 9.67% (FCF TTM 5.51b / Enterprise Value 56.97b)
FCF Margin = 2.25% (FCF TTM 5.51b / Revenue TTM 244.49b)
Net Margin = 0.68% (Net Income TTM 1.67b / Revenue TTM 244.49b)
Gross Margin = 3.62% ((Revenue TTM 244.49b - Cost of Revenue TTM 235.63b) / Revenue TTM)
Gross Margin QoQ = 3.38% (prev 3.62%)
Tobins Q-Ratio = 0.98 (Enterprise Value 56.97b / Total Assets 58.08b)
Interest Expense / Debt = 0.97% (Interest Expense 88.0m / Debt 9.03b)
Taxrate = 25.24% (159.0m / 630.0m)
NOPAT = 1.81b (EBIT 2.42b * (1 - 25.24%))
Current Ratio = 0.91 (Total Current Assets 39.23b / Total Current Liabilities 43.31b)
Debt / Equity = -3.34 (negative equity) (Debt 9.03b / totalStockholderEquity, last quarter -2.70b)
Debt / EBITDA = 1.93 (Net Debt 6.25b / EBITDA 3.23b)
Debt / FCF = 1.14 (Net Debt 6.25b / FCF TTM 5.51b)
Total Stockholder Equity = -2.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 1.67b / Total Assets 58.08b)
RoE = -58.93% (negative equity) (Net Income TTM 1.67b / Total Stockholder Equity -2.83b)
RoCE = 43.79% (EBIT 2.42b / Capital Employed (Equity -2.83b + L.T.Debt 8.35b))
RoIC = 31.74% (NOPAT 1.81b / Invested Capital 5.69b)
WACC = 5.90% (E(50.72b)/V(59.74b) * Re(6.82%) + D(9.03b)/V(59.74b) * Rd(0.97%) * (1-Tc(0.25)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -3.89%
[DCF] Terminal Value 84.94% ; FCFF base≈5.51b ; Y1≈4.84b ; Y5≈3.96b
[DCF] Fair Price = 482.2 (EV 119.71b - Net Debt 6.25b = Equity 113.46b / Shares 235.3m; r=6.0% [WACC]; 5y FCF grow -14.88% → 3.0% )
EPS Correlation: 75.54 | EPS CAGR: 17.21% | SUE: 2.03 | # QB: 2
Revenue Correlation: 88.84 | Revenue CAGR: 10.61% | SUE: 0.11 | # QB: 0
EPS current Year (2026-06-30): EPS=10.31 | Chg7d=+0.004 | Chg30d=+0.004 | Revisions Net=+14 | Growth EPS=+25.1% | Growth Revenue=+16.1%
EPS next Year (2027-06-30): EPS=11.58 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+16 | Growth EPS=+12.3% | Growth Revenue=+8.9%
[Analyst] Revisions Ratio: +1.00 (14 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = +4.2% (Analyst 8.9% - Implied 4.7%)
External Resources